The Ego Goes Quiet, and So Does the Pattern: What Psychedelics Actually Do to the Psychology of Addiction

Psilocybin and MDMA don’t work by blocking receptors or replacing drugs. They interrupt the mental architecture that addiction builds over years.

Psilocybin suppresses the default mode network. MDMA reduces amygdala reactivity during trauma processing. Ibogaine resets mu-opioid signaling. Here’s what the science says about the psychology of psychedelic therapy for addiction.

Jun 1610 minRead

Latest

Arizona WatchJun 16

Arizona Released Its Annual Substance Use Report. Meth Is Now the Primary Story.

AHCCCS’s SFY2025 Annual Substance Use Treatment Report documents a shift in Arizona: methamphetamine presentations are now outpacing opioid-primary cases in parts of Maricopa and Pima counties. The evidence-based treatment for meth still isn’t consistently covered.

Science & MedicineJun 16

France Just Approved IV Ketamine for Suicidal Crisis. The US Has an Excuse, Not an Answer.

France’s ANSM became the first national regulator anywhere to authorize IV racemic ketamine for adult acute suicidal crisis. The US approved esketamine in 2019 but won’t standardize IV ketamine—because it’s a generic with no commercial sponsor.

Harm ReductionJun 16

69,973 Deaths. The Number That Proves Harm Reduction Works—and the Policy Quietly Undoing It.

CDC provisional data projects 69,973 overdose deaths for 2025—a 13.9% decline. The same spring, SAMHSA ended federal funding for fentanyl test strips. The drug supply has never been more dangerous.

More reporting

Full archive

Every substance,
in one place.

Living reference pages on every drug class Rize covers — the science, the policy, the treatment options, and the latest reporting, gathered in one evergreen hub per substance.

Explore the hub

The Ego Goes Quiet, and So Does the Pattern: What Psychedelics Actually Do to the Psychology of Addiction

Latest

Arizona Released Its Annual Substance Use Report. Meth Is Now the Primary Story.

France Just Approved IV Ketamine for Suicidal Crisis. The US Has an Excuse, Not an Answer.

69,973 Deaths. The Number That Proves Harm Reduction Works—and the Policy Quietly Undoing It.

More reporting

The FDA Just Cleared the First US Ibogaine Trial. It Took 30 Years.

Psychedelic and Dissociative Drugs as Medicines

Naltrexone augmented with prazosin for alcohol use disorder: results from a randomized controlled proof-of-concept trial

Relationship between attentional bias and psychological craving in methamphetamine use disorder

Arizona Addiction Treatment Funding 2026: New Resources

The association between cannabis and depression: an updated Systematic Review and Meta-analysis

Responding to the Emerging Threat of Xylazine

Arizona Has $1.2 Billion to Fix Its Addiction Crisis. Here Is What Is Happening to the Money.

Two Kinds of Wanting: How Methamphetamine Craving Actually Works in the Brain

Sections

The Crisis, By the Numbers

Policy & Funding

Treatment & Recovery

Science & Medicine

Harm Reduction

Arizona Watch

Technology & Innovation

Lived Experience & Community

Daily Pulse

Research Roundup

Every substance,
in one place.

The Ego Goes Quiet, and So Does the Pattern: What Psychedelics Actually Do to the Psychology of Addiction

Latest

Arizona Released Its Annual Substance Use Report. Meth Is Now the Primary Story.

France Just Approved IV Ketamine for Suicidal Crisis. The US Has an Excuse, Not an Answer.

69,973 Deaths. The Number That Proves Harm Reduction Works—and the Policy Quietly Undoing It.

More reporting

The FDA Just Cleared the First US Ibogaine Trial. It Took 30 Years.

Psychedelic and Dissociative Drugs as Medicines

Naltrexone augmented with prazosin for alcohol use disorder: results from a randomized controlled proof-of-concept trial

Relationship between attentional bias and psychological craving in methamphetamine use disorder

Arizona Addiction Treatment Funding 2026: New Resources

The association between cannabis and depression: an updated Systematic Review and Meta-analysis

Responding to the Emerging Threat of Xylazine

Arizona Has $1.2 Billion to Fix Its Addiction Crisis. Here Is What Is Happening to the Money.

Two Kinds of Wanting: How Methamphetamine Craving Actually Works in the Brain

Sections

The Crisis, By the Numbers

Policy & Funding

Treatment & Recovery

Science & Medicine

Harm Reduction

Arizona Watch

Technology & Innovation

Lived Experience & Community

Daily Pulse

Research Roundup

Every substance,in one place.

Every substance,
in one place.